Safety, scrutiny and conflicts: Assessing the fallout and lessons learned from pharmaceuticals

Photomedicine and Laser Surgery

Volumn 23, Issue 1, 2005, Pages 1-2

  Lanzafame, Raymond J ^a  

^a Laser Center RGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CERIVASTATIN; ERYTHROMYCIN; GEMFIBROZIL; HISTAMINE H2 RECEPTOR ANTAGONIST; NAPROXEN; PROTON PUMP INHIBITOR; ROFECOXIB;

ARTHRITIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG SAFETY; EDITORIAL; HEART DEATH; HEART INFARCTION; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; PNEUMONIA; RHABDOMYOLYSIS; SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; LACTONES; MASS MEDIA; PRODUCT SURVEILLANCE, POSTMARKETING; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 14844335667     PISSN: 15495418     EISSN: None     Source Type: Journal    
DOI: 10.1089/pho.2005.23.1     Document Type: Editorial

References (12)

1. Murphy's Laws. http:\dmawww.epfl.ch/roso.mosaic/dm/murphy.html
2. Murphy's Law Was Invented Here! http:\www.edwards.af.mil/history/ docs_html/tidbits/murphy's_law.html
3. Psaty BM, Furberg CD, Ray WA, Weiss NS. (2004). Potential for conflicts of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis. JAMA 292(21):2622-2631.
4. Fontanarosa PB, Rennie D, DeAngelis CD. (2004). Postmarketing surveillance-Lack of vigilance, lack of trust. JAMA 292(21):2647-2650.
5. Piorkowski JD. (2004). Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis. JAMA 292(21):2655-2659.
6. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. (2004). Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl J. Med 351(11):1089-1096.
7. Laheij RJ, Sturkenboom MCJM, Hassing RJ, Dieleman J, Stricker BHC, Jansen JBMJ. (2004). Risk of community-acquired pneumonia: use of gastric acid-suppressive drugs. JAMA 292(16):1995-1960.
8. Warner TD, Roberts LW. (2004). Scientific integrity, fidelity and conflicts of interest. Curr Opin Psychiatry 17(5):381-385.
9. Strom BL. (2004). Potential for conflict of interest in the evaluation of suspected adverse drug reactions. JAMA 292(21):2643-2646.
10. Daly JM. (2004). Surgical simulation: Beyond 'to be or not to be'. Contemp Surg 60(12):552.
11. Gallagher AG, Cates CU. (2004). Approval of virtual reality training for carotid stenting. JAMA 292(24):3024-3026.
12. Gladwell M. (2004). The picture problem: Mammography, air power, and the limits of looking. The New Yorker, December 13, 2004.